Barclays Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

In a report issued on November 10, Gena Wang from Barclays maintained a Buy rating on Arcturus Therapeutics (ARCTResearch Report), with a price target of $68.00. The company’s shares closed last Wednesday at $48.84.

According to, Wang is a 5-star analyst with an average return of 16.6% and a 50.0% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcturus Therapeutics with a $72.50 average price target, representing a 74.1% upside. In a report issued on November 2, Piper Sandler also maintained a Buy rating on the stock with a $77.00 price target.

See today’s analyst top recommended stocks >>

Based on Arcturus Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.32 million and GAAP net loss of $10.26 million. In comparison, last year the company earned revenue of $10.15 million and had a GAAP net loss of $685K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.